ALAMEDA, Calif., June 11, 2026
Penumbra, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for THUNDERBOLT™, expanding the company’s Computer Assisted Vacuum Thrombectomy (CAVT™) technology into the treatment of acute ischemic stroke. The newly cleared platform is the first CAVT system approved for stroke care that utilizes modulated aspiration technology to facilitate faster and more complete blood clot removal. The milestone strengthens Penumbra’s leadership in thrombectomy innovation and introduces a new approach designed to improve outcomes for patients suffering from life-threatening stroke caused by large vessel occlusions.
THUNDERBOLT Introduces Advanced Clot Removal Technology for Stroke Care
Powered by the Penumbra ENGINE™, THUNDERBOLT brings a novel method of clot extraction to neurovascular intervention. The system uses modulated aspiration, a technology engineered to detect, fatigue, capture, and fully ingest blood clots directly at the site of blockage. Unlike traditional approaches that may require repeated catheter manipulation, THUNDERBOLT is designed to promote efficient clot removal while minimizing procedural complexity. The technology aims to rapidly restore blood flow to the brain, a critical factor in reducing neurological damage and improving recovery outcomes for stroke patients.
FDA Clearance Expands Penumbra’s Leadership in Thrombectomy Innovation
Acute ischemic stroke remains one of the leading causes of death and long-term disability worldwide, making rapid intervention essential. Industry experts believe THUNDERBOLT could significantly advance the standard of care by enabling more consistent clot retrieval and improved vessel reopening rates. As the only FDA-cleared CAVT device available for stroke treatment in the United States, THUNDERBOLT represents a first-of-its-kind innovation in neurovascular medicine. The platform will be offered pre-packaged with several of Penumbra’s established thrombectomy catheters, including RED™ 62, RED™ 68, RED™ 72 SILVER LABEL, and RED™ 72 SILVER LABEL with SENDit™ technology, supporting seamless integration into existing stroke treatment workflows.
Advertisement
New Era of Stroke Management and Neurovascular Intervention
Penumbra stated that the FDA clearance reflects its long-standing commitment to redefining stroke treatment through technological innovation. The company now offers CAVT technology across both vascular and neurovascular applications, addressing blood clot removal throughout the body. With stroke incidence and mortality projected to rise globally over the coming decades, advancements that improve speed, safety, and effectiveness of treatment are increasingly important. THUNDERBOLT marks a significant expansion of Penumbra’s thrombectomy portfolio and positions the company at the forefront of next-generation stroke intervention technologies aimed at improving patient survival and quality of life.
Source: Penumbra press release
